Clinical Trials
20 trialsNCT05377996 2026-04-14
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
Phase 1 Recruiting
NCT06118086 2026-02-18
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Remix Therapeutics
Phase 1/2 Recruiting
NCT05194072 2026-01-09
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT06462183 2025-11-14
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Rgenta Therapeutics Inc
Phase 1 Recruiting
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT06781567 2025-03-14
HG146
HitGen Inc.
Phase 2 Recruiting
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT04249947 2025-02-17
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Phase 1 Terminated
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT04119453 2024-06-24
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Elevar Therapeutics
Phase 2 Terminated
NCT03691207 2024-01-31
ACCURACY
Ayala Pharmaceuticals, Inc,
Phase 2 Completed
NCT03422679 2024-01-16
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Phase 1/2 Terminated
NCT04706845 2023-09-29
Understanding the Burden of ACC Through the Eyes of Patients
Ayala Pharmaceuticals, Inc,
Completed
NCT03886831 2023-03-28
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT04832438 2022-02-22
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
Phase 2 Withdrawn
NCT03291002 2021-11-04
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
CureVac
Phase 1 Unknown
NCT03680560 2020-03-31
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Cogent Biosciences, Inc.
Phase 1 Terminated
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed